PDCD1 and breast carcinoma: The investigators analyzed a large dataset of 2,881 ICI-treated (PD-1/PD-L1 inhibitor or CTLA-4 inhibitor or a combination of both) and 841 non-ICI-treated patients across 18 solid tumor types, including breast cancer.